Witnessing the stock’s movement on the chart, on Wednesday, Galectin Therapeutics Inc (NASDAQ: GALT) set off with pace as it heaved 2.35% to $2.84, before settling in for the price of $2.77 at the close. Taking a more long-term approach, GALT posted a 52-week range of $1.55-$4.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was -14.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 1.35%. This publicly-traded company’s shares outstanding now amounts to $61.85 million, simultaneously with a float of $43.59 million. The organization now has a market capitalization sitting at $177.93 million. At the time of writing, stock’s 50-day Moving Average stood at $2.70, while the 200-day Moving Average is $2.62.
Galectin Therapeutics Inc (GALT) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Galectin Therapeutics Inc’s current insider ownership accounts for 30.54%, in contrast to 15.56% institutional ownership. According to the most recent insider trade that took place on Oct 23 ’24, this organization’s Director bought 500 shares at the rate of 2.60, making the entire transaction reach 1,300 in total value, affecting insider ownership by 50,213. Preceding that transaction, on Oct 17 ’24, Company’s Director bought 1,300 for 2.64, making the whole transaction’s value amount to 3,432. This particular insider is now the holder of 34,769 in total.
Galectin Therapeutics Inc (GALT) Earnings and Revenue Records
Galectin Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 1.35% and is forecasted to reach -1.65 in the upcoming year.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
Let’s observe the current performance indicators for Galectin Therapeutics Inc (GALT). It’s Quick Ratio in the last reported quarter now stands at 1.13. The Stock has managed to achieve an average true range (ATR) of 0.17.
In the same vein, GALT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.73, a figure that is expected to reach -0.16 in the next quarter, and analysts are predicting that it will be -1.65 at the market close of one year from today.
Technical Analysis of Galectin Therapeutics Inc (GALT)
Going through the that latest performance of [Galectin Therapeutics Inc, GALT]. Its last 5-days volume of 0.21 million indicated improvement to the volume of 0.15 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 37.24% While, its Average True Range was 0.17.
Raw Stochastic average of Galectin Therapeutics Inc (GALT) in the period of the previous 100 days is set at 71.85%, which indicates a major rise in contrast to 36.07% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.26% that was lower than 57.21% volatility it exhibited in the past 100-days period.
